Bayesian construction of an improved parametric test for probability-based individual bioequivalence

Biometrical Journal

Volumn 42, Issue 8, 2000, Pages 1039-1052

  Wellek, Stefan ^a  

^a J5   (Germany)

Author keywords

Exact power function; Gauss Legendre integration; Individual bioequivalence; Reference prior; TIER

Indexed keywords

BIOCHEMISTRY;

BAYESIAN; BAYESIAN TEST; EXACT POWER; EXACT POWER FUNCTION; GAUSS-LEGENDRE INTEGRATION; INDIVIDUAL BIOEQUIVALENCE; PARAMETRIC TEST; POWER FUNCTIONS; REFERENCE PRIOR; TIER;

STATISTICAL TESTS;

EID: 0034551205     PISSN: 03233847     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4036(200012)42:8<1039::AID-BIMJ1039>3.0.CO;2-1     Document Type: Article

References (20)

1. ABRAMOWITZ, M. and STEGUN, I., 1965: Handbook of Mathematical Functions. Dover Publications, New York.
2. ANDERSON, S. and HAUCK, W.W., 1990: Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 18, 259-273.
3. BILLINGSLEY, P., 1979: Probability and Measure. John Wiley & Sons, New York.
4. BOX, G.P.E. and TIAO, G. C., 1973: Bayesian Inference in Statistical Analysis. Addison-Wesley, Reading, Mass.
5. CHEN, M.-L., 1997: Individual Bioequivalence - A Regulatory Update. Journal of Biopharmaceutical Statistics 7, 5-11.
6. CHOW, S.-C. and LIU, J.-P., 1992: Design and Analysis of Biovailability and Bioequivalence Studies. Marcel Dekker, Inc, New York.
7. DAVIS, P. J. and RABINOWITZ, P., 1975: Methods of Numerical Integration. Academic Press, New York.
8. FOOD and DRUG ADMINISTRATION (FDA), 1999: Guidance for Industry: Average, Population, and Individual Approaches to Establishing Bioequivalence. Draft Guidance. Center for Drug Evaluation and Research, Rockville, MD.
9. JONES, B. and KENWARD, M. G., 1989: Design and Analysis of Cross-Over Trials. Chapman and Hall, London.
10. MANDALLAZ, D. and MAU, J., 1981: Comparison of different methods for decision making in bioequivalence assessment. Biometrics 37, 213-222.
11. SCHALL, R., 1995: Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar. Biometrics 51, 615-626.
12. SCHALL, R. and LUUS, H. G., 1993: On population and individual bioequivalence. Statistics in Medicine 12, 1109-1124.
13. SCHUIRMANN, D. J., 1987: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 15, 657-680.
14. SHEINER, L. B., 1992: Bioequivalence revisited. Statistics in Medicine 11, 1777-1788.
15. WELLEK, S., 1990: Vorschläge zur Reformulierung der statistischen Definition von Bioäquivalenz. In: G. Giani, R. Repges (Ed.): Biometrie und Informatik - neue Wege der Erkenntnisgewinnung in der Medizin. Springer-Verlag, Berlin, 95-99.
16. WELLEK, S., 1991: Zur Formulierung und optimalen Lösung des Bioäquivalenznachweis-Problems in der klassischen Theorie des Hypothesentestens. In: J. Vollmar (Ed.): Bioäquivalenz sofort freisetzender Arzneiformen. Gustav Fischer, Stuttgart, 91-109.
17. WELLEK, S., 1993: Basing the analysis of comparative bioavailability trials on an individualized statistical definition of equivalence. Biometrical Journal 35, 47-55.
18. WELLEK, S., 1994: Statistische Methoden zum Nachweis von Äquivalenz. Gustav Fischer, Stuttgart.
19. WELLEK, S., 1996: A new approach to equivalence assessment in standard comparative bioavailability trials by means of the Mann-Whitney statistic. Biometrical Journal 38, 695-710.
20. WELLEK, S., 2000: On a reasonable disaggregate criterion of population bioequivalence admitting of resampling-free testing procedures. Statistics in Medicine 19, 2755-2767.